A report from GHTC and Policy Cures Research examines how US federal funding for global health R&D is delivering impact both abroad and at home.

Search the GHTC website

Alabama

Alabama

Global health R&D delivers for Alabama

US government investment in global health R&D has delivered

Amount
$196.8 million
to Alabama research institutions
Jobs
2,500+ new jobs
for Alabama
Alabama's top USG-funded global health R&D institutions

Alabama's top USG-funded global health R&D institutions

University of Alabama at Birmingham
$144 million
Southern Research Institute
$45.8 million
SunFire Biotechnologies LLC
$1.3 million
Auburn University
$1.2 million
GeneCapture Inc.
$1.2 million
University of South Alabama (Including College of Medicine)
$1.2 million
CFD Research Corporation
$701 thousand
Adjuvax LLC
$600 thousand
Cnine Biosolutions Inc.*
$415 thousand
FoodSource Lure Corporation
$257 thousand
SIO2 Medical Products Inc.
$173 thousand

Alabama's top areas of global health R&D by USG funding

3.2%
Bacterial pneumonia & meningitis
2.8%
Chikungunya
6.7%
COVID-19
5%
Other coronaviruses (including MERS, SARS)
2.1%
Hepatitis B
43.4%
HIV/AIDS
2.3%
Malaria
4.3%
Neglected tropical diseases
Dengue
Kinetoplastid diseases
7.1%
Reproductive health
16.9%
Tuberculosis
6.2%
Other
Bunyaviral diseases (including CCHF, RVF, SFTS)
Diarrheal diseases
Emergent non-polio enteroviruses (including EV71, D68)
Filoviral diseases (including Ebola, Marburg)
Hepatitis C
Multi-disease/health area R&D
Rheumatic fever
Zika
Alabama

Neglected and emerging diseases in Alabama

Chikungunya cases
Chikungunya cases
22
Dengue cases
Dengue cases
44
HIV diagnoses
HIV diagnoses
9237
Malaria cases
Malaria cases
126
Malaria cases
Mpox cases
192
Tuberculosis cases
Tuberculosis cases
1894
Global health R&D at work in Alabama

The University of Alabama at Birmingham Heersink School of Medicine operates the Antiviral Drug Discovery and Development Center (AD3C), funded by the US National Institutes of Health. AD3C focuses on developing drug therapies for diseases such as influenza, West Nile virus, chikungunya, dengue, and coronaviruses, including COVID-19. Researchers work to target and inhibit enzymes essential for viral replication. The viruses that AD3C targets are of high priority for the US government as the global burden of these diseases is enormous, and many also pose a risk to US citizens. Southern Research in Birmingham is supporting AD3C in screening potential compounds.

Footnotes
  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: NIAID